Close Menu

Jeffrey Field

Sep 15, 2015

Jeffrey Field has joined GenePeeks as Chief Commercial Officer, where he will lead global expansion of the firm's pre-conception risk prediction products and services.

Field joins GenePeeks from Foundation Medicine, where he helped develop and exectue that company's commercial strategy and launch plan for its comprehensive genomic profling services as VP of Sales and Client Services. He brings more than 20 years of experience, having also worked at Caris Life Sciences and Astra Merck.

More Like This

Mar 22, 2019

John Niederhuber, Judy Garber, Geoffrey Ginsburg, Giovanni Parmigiani, David Rimm, Howard Scher

Konica Minolta Precision Medicine has announced the formation of its scientific advisory board, which include John Niederhuber, Judy Garber, Geoffrey Ginsburg, Giovanni Parmigiani, David Rimm, and Howard Scher. John Niederhuber has also been appointed as the board's chairman.

Niederhuber is currently CEO of the Genomics and Bioinformatics Research Institute, and formerly served as the director of the National Cancer Institute  and the National Institutes of Health.

Garber is currently chief of the division of cancer genetics and prevention at the Dana-Farber Cancer Institute, as well as a professor at Harvard Medical School.

Ginsburg currently serves as the founding director at the center for applied genomics & precision medicine at the Duke University Medical Center.

Parmigiani is currently associate director for population sciences of the multi-institutional Dana-Farber/Harvard Cancer Center, as well as director of the postdoctoral training grant in quantitative sciences for Cancer research at the Harvard T.H. Chan School of Public Health.

Rimm currently serves as professor of pathology and medicine at the Yale University School of Medicine, as well as the director of Yale Pathology Tissue Services.

Scher acts as the co-chair for mechanism based therapy and head of the biomarker development initiative at Memorial Sloan Kettering Cancer Center.

Mar 20, 2019

Ted Snelgrove

Liquid biopsy firm Lexent Bio has appointed Ted Snelgrove as its chief business officer. In the roll, Snelgrove will work closely with the CEO and  the company's board on test launch strategy, commercial team development, and corporate partnering.

Snelgrove's experience in molecular diagnostics includes building and leading the original commercial team for Genomic Health's Oncotype DX product line. He also built the commercial team at Crescendo Bioscience, now part of Myriad Genetics, promoting the firm's Vectra DA for disease management in rheumatology. He was CEO at CellScape, an early player in the NIPT market, served as the oncology/hematology business unit head at Jazz Pharmaceuticals, and held C-Level roles at Counsyl and more recently at Guardant Health.

Mar 14, 2019

Michael Ball

Contextual Genomics has appointed Michael Ball as the firm's CEO. He previously served as global VP of commercial, informatics, at Illumina. Prior to Illumina, Ball acted as CEO of GenoLogics Life Sciences Software. He is currently a director of the Canary Foundation, a non-profit focused on early cancer detection.

Mar 12, 2019

Norman Sharpless

The US Health and Human Services Secretary Alex Azar has appointed Norman Sharpless as acting commissioner of the US Food and Drug Administration. Sharpless, currently the director of the National Cancer Institute, will take over for current FDA Commissioner Scott Gottlieb who announced on March 5 that he will resign from the post in one month. Before his position at the NCI, Sharpless directed the University of North Carolina's Lineberger Comprehensive Cancer Center, authored more than 100 research papers, and treated leukemia patients.

Mar 12, 2019

Patricia Rivera

Bioaffinity Technologies has formed a scientific and medical advisory board and named Patricia Rivera as the chairperson. Rivera is a professor of pulmonary diseases and critical care medicine at the University of North Carolina School of Medicine. She is also director of the UNC Lung Cancer Screening Clinic.

Mar 06, 2019

Todd Druley, Sandra Close, Karen Fritschen,

ArcherDx has appointed Todd Druley as the firm's chief medical officer, Sandra Close as the senior VP of regulatory and diagnostic strategy, and Karen Fritschen as VP of human resources.

Prior to joining ArcherDx, Druley most recently served as an associate professor of pediatrics, hematology, and oncology at Washington University of Medicine in St. Louis. He is an inductee into the American Society of Clinical Investigators and serves as a scientific advisor for Alex's Lemonade Stand Foundation, the Gateway Chapter of the Leukemia & Lymphoma Society, the Kids Shouldn't Have Cancer Foundation, the B+ Foundation, and the Eli Seth Matthews Leukemia Foundation. Druley will continue to see children with cancer predisposition as well as oversee his academic research lab at WUSTL.

Before joining ArcherDx, Close served as CEO of GenEngine. In addition she was responsible for building the health outcomes function for Baxter Healthcare/Caremark. She also lead the research and biomarker functions, including personalized medicine and companion diagnositics at Eli Lilly. Close also previously served as Arrogen's chief scientific officer.

Mar 05, 2019

Colin McCracken

Colin McCracken has joined Fluidigm as chief commercial officer. Prior to joining Fluidigm McCracken was vice president of chromatography and mass spectrometry, EMEA, for Thermo Fisher Scientific. He also previously led commecial operations in Europe for Invitrogen and Life Technologies, and has worked with Bristol-Myers Squibb.

Mar 04, 2019

Kathleen Sebelius

Exact Sciences has appointed Kathleen Sebelius to serve as a director on its board. She will sit on the firm's corporate governance and nominating committee and on its innovation, technology and pipeline committee. Sebelius currently serves as CEO of Sebelius Resources, a strategic consulting firm that advises private companies, non-profit organizations, and financial investors. From April 2009 through June 2014, she served as the Health and Human Services Secretary for President Barack Obama. She also served as Governor of Kansas from 2003 to 2009, and her previous elected offices include two terms as the Kansas insurance commissioner and four terms in the Kansas legislature.

Sebelius currently sits on the boards of biopharmaceutical companies Dermira and Myovant Sciences, as well as the Kaiser Family Foundation. She also co-chairs the Aspen Institute Health Strategy Group and serves on advisory boards for the Dole Institute of Politics, Solera Health, Out Leadership, the Estée Lauder Foundation, and the University of Kansas College of Liberal Arts and Sciences.

Feb 27, 2019

Todd Wood

DermTech has appointed Todd Wood as the firm's chief commercial officer. Wood brings 25 years of pharmaceutical and medical device commercialization experience to the firm. He has previously launch multiple market products, including Juvéderm, Limigan, and Rhofade.

Feb 26, 2019

Geoff Smith, Robert Nicol

DNA Script has formed a scientific advisory board, appointing Geoff Smith to serve as chair and Robert Nicol to serve as a second board member.

Smith is an expert in genomic technologies and their applications, having spent more than 10 years working as a vice president at Solexa/Illumina where he led the development of many aspects of the core SBS sequencing chemistry, workflows and platforms, and cell-free DNA pregnancy testing portfolio. After leaving Illumina, Smith served as CEO of Cambridge Epigenetix, and he now works as an advisor to a variety of companies in the genomics space.

Nicol serves as director of the technology labs at the Broad Institute. He is also the cofounder of the MIT-Broad Foundry for Synthetic Biology. Nicol joined the Whitehead Institute/MIT Center for Genome Research in 2001, and directed the sequencing operations and technology development groups at the Broad for more than 12 years.

Feb 26, 2019

Jack Crowley, Kavita Patel, Garry Nicholson

Personal Genome Diagnostics has appointed Jack Crowley as its chief financial officer. Crowley most recently served as CFO at Lantheus Medical Imaging, where he led a transition from a private equity-backed to a publicly-traded global life sciences company. Prior to serving as CFO, Crowley also served as Lantheus' chief accounting officer, VP of finance, and global corporate controller. He also served as director of finance and assistant corporate controller at Biogen and director of accounting at Thermo Fischer Scientific. A Certified Public Accountant, he holds an MBA from the University of Massachusetts and a BS in Business Administration from Westfield State University.

PGDx has also appointed Kavita Patel and Garry Nicholson to its board of directors. Patel has served in the Obama Administration as director of policy for the Office of Intergovernmental Affairs and Public Engagement in the White House. Prior to the White House, she served as deputy staff director on health on the late Senator Edward Kennedy's staff. She also serves on the board of directors at Dignity Health and SSM Health Care. 

Nicholson currently serves as director at Five Prime Therapeutics, G1 Therapeutics, Tmunity Therapetics Inc, and SQZ Biotechnology. He previously served as President and CEO of XTuit Pharmaceuticals, as well as a member of the firm's board of directors. Prior to that, he served as president of Pfizer Oncology. He has also served on the Pfizer Foundation's board of directors and was a member of the firm's Portfolio, Strategy, and Investment Committee. In addition, Nicholson previously held leadership positions in the oncology division of Eli Lily. 

Feb 25, 2019

Laurie Heilmann

Laurie Heilmann has been appointed as senior vice president of business development and marketing at protein engineering company Codexis. Most recently, she was president of global life sciences and diagnostics, and before that, chief business officer and senior vice president of global strategy, business development, and marketing at Crown Bioscience.  

Feb 25, 2019

Don Elsey

OpGen has appointed Don Elsey to its board of directors and as the chairman of its audit committee. Elsey previously served as chief financial officer of Senseonics from 2015 to 2019. Prior to Senseonics, Elsey served as CFO of Regado Biosciences. He as also served as CFO of LifeCell and Emergent Biosolutions. In addition, Elsey has held senior financial positions at BioVeris, Igen, and PE (Applera). 

Feb 22, 2019

Jeffrey Alter, John Bigalke, Samuel Nussbaum, Lynne Powell

Progenity has appointed Jeffrey Alter, John Bigalke, Samuel Nussbaum, and Lynne Powell to its board of directors.

Alter is president of Arcturus One Consulting. He previously served as CEO of UnitedHealthcare's commercial group. Prior to that, he was senior VP of strategic financial planning for Oxford Health Plans. Before Oxford, he served as VP of finance, underwriting, and operations at Vytra Health Plans.

Bigalke is CEO of Second Half Healthcare Advisors. He is also chairman of VaxCares' advisory board and a member of Advent (formerly Adventist) Health System's advisory board. In addition, he is a senior advisor to Concord Management Services. Bigalke previously served as US national industry leader and senior partner for global healthcare and life sciences at Deloitte. Bigalke also was the firm's national director of public policy.

Nussbaum is a professor of clinical medicine at the Washington University School of Medicine. He is also a strategic consultant for EBG Advisors and a senior advisor to Sandbox Industries and the Ontario Teachers' Pension Plan. He serves on several boards, including those of Motus GI, Coherus Biosciences, and PhyMed. Prior to this, Nussbaum served as executive VP of clinical health policy and chief medical officer at Anthem. Previously, he was executive VP of medical affairs and system integration at BJC Healthcare. 

Powell serves as senior VP and chief commercial officer at BioCryst Pharmaceuticals. Prior to this, she was senior VP of North America at CSL Behring. Powell also served as the firm's VP of global commercial development and head of business development and European marketing. Prior to CSL, she held positions at Glaxo Wellcome's commercial strategy and clinical research organizations.

Feb 19, 2019

Anthony Schmidt

Circulogene has named Anthony Schmidt as the firm's medical director. He will lead the lab's precision medicine initiatives and educate the medical community about the firm's technologies. Schmidt was most recently pathology chair and lab medical director for the Mississippi Baptist Healthcare System.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.